Celcuity (NASDAQ:CELC) Shares Gap Down on Disappointing Earnings

Key Points

• Celcuity’s shares fell after disappointing second-quarter results, opening at $83.04 versus a prior close of $86.60. The company reported a $1.44 per-share loss, compared with the expected $1.16 loss, while revenue of $0.09 million was far below the $4.42 million consensus estimate.
• Analysts lowered their price targets following the results, including Needham to $140 and Stifel to $150, but both maintained Buy ratings. Overall, ten analysts rate the stock Buy and one rates it Sell, producing a “Moderate Buy” consensus and an average target of $153.64.
• Celcuity remains a clinical-stage precision oncology company developing biomarker assays to help identify effective targeted cancer treatments. Institutional investors own approximately 63.33% of its shares.

Shares of Celcuity, Inc. (NASDAQ:CELC - Get Free Report) gapped down prior to trading on Friday following a dissappointing earnings announcement. The stock had previously closed at $86.60, but opened at $83.04. Celcuity shares last traded at $89.8930, with a volume of 239,349 shares changing hands.

The company reported ($1.44) EPS for the quarter, missing the consensus estimate of ($1.16) by ($0.28). The business had revenue of $0.09 million for the quarter, compared to the consensus estimate of $4.42 million.

Celcuity News Roundup

Here are the key news stories impacting Celcuity this week:

• Positive Sentiment: Stifel Nicolaus maintained a Buy rating while lowering its price target from $175 to $150, implying substantial upside from the referenced price. Benzinga analyst rating coverage
• Positive Sentiment: Needham & Company also kept a Buy rating and reduced its target from $157 to $140, signaling that analysts still see meaningful potential in Celcuity despite the revisions. Benzinga analyst rating coverage
• Neutral Sentiment: Celcuity released its second-quarter 2026 results and provided a corporate update. Investors are reviewing management’s development and commercialization progress for its targeted cancer therapies. Celcuity second-quarter 2026 results and corporate update
• Negative Sentiment: Celcuity reported a second-quarter loss of $1.44 per share, wider than the consensus loss estimate of $1.16, while revenue of approximately $0.09 million fell far short of the $4.42 million estimate. The results prompted analysts to slash forecasts, increasing concern about commercialization timing and near-term financial performance. Celcuity analysts lower forecasts after second-quarter loss

Wall Street Analysts Forecast Growth

CELC has been the topic of several research analyst reports. Needham & Company LLC lowered their price objective on shares of Celcuity from $157.00 to $140.00 and set a "buy" rating on the stock in a research report on Friday. Citigroup restated an "outperform" rating on shares of Celcuity in a report on Wednesday, July 15th. HC Wainwright raised their target price on Celcuity from $145.00 to $155.00 and gave the stock a "buy" rating in a research report on Wednesday, July 15th. Citizens Jmp lifted their price target on Celcuity from $160.00 to $177.00 and gave the company a "market outperform" rating in a report on Wednesday, July 15th. Finally, Guggenheim reissued a "buy" rating on shares of Celcuity in a research report on Wednesday, June 3rd. Ten investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $153.64.

Institutional Investors Weigh In On Celcuity

A number of institutional investors have recently modified their holdings of the stock. EverSource Wealth Advisors LLC increased its stake in shares of Celcuity by 1,329.2% in the fourth quarter. EverSource Wealth Advisors LLC now owns 343 shares of the company's stock worth $34,000 after acquiring an additional 319 shares during the last quarter. US Bancorp DE boosted its position in Celcuity by 25.4% during the third quarter. US Bancorp DE now owns 706 shares of the company's stock valued at $35,000 after purchasing an additional 143 shares during the last quarter. BNP Paribas Financial Markets grew its stake in Celcuity by 78.9% in the second quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company's stock valued at $35,000 after purchasing an additional 1,167 shares in the last quarter. Parallel Advisors LLC purchased a new position in Celcuity in the first quarter valued at about $38,000. Finally, Meeder Asset Management Inc. acquired a new position in Celcuity in the 4th quarter worth about $42,000. Institutional investors and hedge funds own 63.33% of the company's stock.

Celcuity Stock Performance

The firm has a 50-day simple moving average of $93.81 and a two-hundred day simple moving average of $108.56. The company has a current ratio of 12.31, a quick ratio of 12.31 and a debt-to-equity ratio of 6.04. The company has a market capitalization of $4.39 billion, a price-to-earnings ratio of -23.10 and a beta of 0.20.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source